Accurate assessment of ErbB2 in early breast cancer and metastases is clinically important because expression levels may correlate with tumor aggressiveness and disease-free survival, and may facilitate patient selection for ErbB2 specific therapies, dose adjustment, changes in treatment schedule, and monitoring of therapeutic response18. Here, ERBB2 is linked to neoplasm.